November 29, 2022

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

GAITHERSBURG, Md., Nov. 29, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.

“Today’s updated Emergency Use Listing from the WHO allows us to offer our protein-based vaccine as a primary series to adolescents and as a booster for adults around the world,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “WHO member countries now have a vaccine option for these indications developed using an innovative approach to traditional technology that can also be stored in standard refrigeration, making it easy to transport.”

Primary Series in Adolescents
The updated EUL for Nuvaxovid as a primary series in adolescents aged 12 through 17 was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,232 adolescents aged 12 through 17 years across 75 sites in the U.S., to evaluate the safety and effectiveness of Nuvaxovid. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

Preliminary safety data from the pediatric expansion showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the pediatric expansion.

Booster in Adults
The updated EUL for Nuvaxovid as a booster in adults aged 18 and older is supported by data from Novavax’ Phase 2 trial conducted in Australia, from a separate Phase 2 trial conducted in South Africa, and from the United Kingdom (U.K.)-sponsored COV-BOOST trial. As part of the Novavax Phase 2 trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after their primary two-dose vaccination series of Nuvaxovid. The third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials. In the COV-BOOST trial, Nuvaxovid induced a meaningful antibody response when used as a heterologous third booster dose.

In the Novavax-sponsored trials, following the booster, local and systemic reactions had a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low. Safety reporting of reactogenicity events showed an increasing incidence across all three doses of Nuvaxovid, often seen with increased immunogenicity. Medically attended adverse events (AE), potentially immune-mediated medical conditions, and severe AEs occurred infrequently following the booster dose and were balanced between vaccine and placebo groups.

In the 12 through 17-year-old population, Novavax’ vaccine has been authorized in more than 10 markets including the U.S., the European Union (EU), and the U.K. The vaccine has also been authorized as a booster in the U.S., EU, Japan, Australia, New Zealand, and Switzerland, and a number of other countries have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose. Novavax’ vaccine is actively under review in other markets for both indications and has ongoing trials to further explore its efficacy and safety as a booster.

The WHO previously granted EUL for Nuvaxovid in adults aged 18 and older in December 2021.

Trade Name in the U.S.
The trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration (FDA).

Important Safety Information: WHO

Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
Events of anaphylaxis have been reported with administration of Nuvaxovid. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
Individuals may not be fully protected until 7 days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
The most frequent adverse reactions in clinical trials in individuals 12 years of age and older were headache, nausea or vomiting myalgia, arthralgia, injection site tenderness, injection site pain, fatigue, and malaise.

For more information on Nuvaxovid, including the Summary of Product Characteristics with Package Leaflet, adverse event reporting instructions, or to request additional information, please visit the following websites:

About Nuvaxovid (NVX-CoV2373)
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization, and distribution of Nuvaxovid worldwide. Existing authorizations leverage Novavax’ manufacturing partnership with Serum Institute of India, the world’s largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax’ global supply chain.

About the Novavax COVID-19 vaccine (NVX-CoV2373) Phase 3 Trials
The Novavax COVID-19 vaccine (NVX-CoV2373) continues being evaluated in two pivotal Phase 3 trials.

PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations in the U.S. and Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, the Novavax COVID-19 vaccine achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM).

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the U.S., compared with placebo. In the pediatric trial, the vaccine achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S. Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM.

About Matrix-M Adjuvant
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S. FDA, the European Commission, and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on LinkedIn.

Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, NVX-CoV2515 and a bivalent Omicron-based / original strain based vaccine, the CIC investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax’ plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax’ global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety, intended utilization, and expected administration of NVX-CoV2373, and the expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Novavax’ Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com

Media
Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com

Logo – https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

November 29, 2022November 30, 2022

Fentanyl’s Scourge Visible on Streets of Los Angeles

In a filthy alley behind a Los Angeles doughnut shop, Ryan Smith convulsed in the grips of a fentanyl high — lurching from moments of slumber to bouts of violent shivering on a warm summer day.

When Brandice Josey, another homeless addict, bent down and blew a puff of fentanyl smoke his way in an act of charity, Smith sat up and slowly opened his lip to inhale the vapor as if it was the cure to his problems.

Smith, wearing a grimy yellow T-shirt that said “Good Vibes Only,” reclined on his backpack and dozed the rest of the afternoon on the asphalt, unperturbed by the stench of rotting food and human waste that permeated the air.

For too many people strung out on the drug, the sleep that follows a fentanyl hit is permanent. The highly addictive and potentially lethal drug has become a scourge across America and is taking a toll on the growing number of people living on the streets of Los Angeles.

Nearly 2,000 homeless people died in the city from April 2020 to March 2021, a 56% increase from the previous year, according to a report released by the Los Angeles County Department of Public Health. Overdose was the leading cause of death, killing more than 700.

Fentanyl was developed to treat intense pain from ailments like cancer. Use of fentanyl, a powerful synthetic opioid that is cheap to produce and is often sold as is or laced in other drugs, has exploded. Because it’s 50 times more potent than heroin, even a small dose can be fatal.

It has quickly become the deadliest drug in the nation, according to the Drug Enforcement Administration. Two-thirds of the 107,000 overdose deaths in 2021 were attributed to synthetic opioids like fentanyl, the U.S. Centers for Disease Control and Prevention said.

The drug’s toll spreads far beyond the streets.

Jennifer Catano, 27, has the names of two children tattooed on her wrists, but she hasn’t seen them for several years. They live with her mother.

She has overdosed three times and been through rehab seven or eight times.

“It’s scary to get off of it,” she said. “The withdrawals are really bad.”

Catano wandered around a subway station near MacArthur Park desperate to sell a bottle of Downy fabric softener and a Coleman camping chair she stole from a nearby store.

Drug abuse can be a cause or symptom of homelessness. Both can also intersect with mental illness.

A 2019 report by the Los Angeles Homeless Services Authority found about a quarter of all homeless adults in Los Angeles County had mental illnesses and 14% had a substance use disorder. That analysis only counted people who had a permanent or long-term severe condition. Taking a broader interpretation of the same data, the Los Angeles Times found about 51% had mental illnesses and 46% had substance use disorders.

Billions of dollars are being spent to alleviate homelessness in California, but treatment is not always funded.

A controversial bill signed by Gov. Gavin Newsom could improve that by forcing people suffering from severe mental illness into treatment. But they need to be diagnosed with a certain disorder such as schizophrenia and addiction alone doesn’t qualify.

Help is available but it is outpaced by the magnitude of misery on the streets.

Rita Richardson, a field supervisor with LA Door, a city addiction-prevention program that works with people convicted of misdemeanors, hands out socks, water, condoms, snacks, clean needles and flyers at the same hotspots Monday through Friday. She hopes the consistency of her visits will encourage people to get help.

“Then hopefully the light bulb comes on. It might not happen this year. It might not happen next year. It might take several years,” said Richardson, a former homeless addict. “My goal is to take them from the dark to the light.”

Source: Voice of America

November 29, 2022November 30, 2022

US Bat Species Devastated by Fungus Now Listed as Endangered

The Biden administration declared the northern long-eared bat endangered on Tuesday in a last-ditch effort to save a species driven to the brink of extinction by white-nose syndrome, a fungal disease.

“White-nose syndrome is decimating cave-dwelling bat species like the northern long-eared bat at unprecedented rates,” said Martha Williams, director of the U.S. Fish and Wildlife Service.

The agency is “deeply committed to working with partners on a balanced approach that reduces the impacts of disease and protects the survivors to recover northern long-eared bat populations,” she said.

First documented in the U.S. in 2006, the disease has infected 12 types of bats and killed millions. The northern long-eared bat is among the hardest hit, with estimated declines of 97% or higher in affected populations. The bat is found in 37 eastern and north-central states, plus Washington, D.C., and much of Canada.

Named for white, fuzzy spots that appear on infected bats, white-nose syndrome attacks bats’ wings, muzzles and ears when they hibernate in caves and abandoned mines.

It causes them to wake early from hibernation and to sometimes fly outside. They can burn up their winter fat stores and eventually starve.

The disease has spread across nearly 80% of the geographical range where northern long-eared bats live and is expected to cover it all by 2025.

Little brown bat also suffering

Another species ravaged by the fungus is the tricolored bat, which the government proposed to classify as endangered in September. A third, the little brown bat, is being evaluated for a potential listing.

Bats are believed to give U.S. agriculture an annual boost of $3 billion by gobbling pests and pollinating some plants.

The Fish and Wildlife Service designated the northern long-eared bat as threatened in 2015. With its situation increasingly dire, the agency proposed an endangered listing in March and considered public comments before deciding to proceed. The reclassification takes effect January 30, 2023.

“This species is in dire straits, but we never want to give up hope,” said Winifred Frick, chief scientist with Bat Conservation International, a nonprofit group. “We can do amazing things when we work hard and have legal protections in place to protect these small colonies that are left.”

In many cases, the service identifies “critical habitat” areas considered particularly important for the survival of an endangered species. Officials decided against doing so for the northern long-eared bat because habitat loss isn’t the primary reason for its decline, spokeswoman Georgia Parham said. Calling attention to their winter hibernation spots could make things worse, she added.

Recovery efforts will focus on wooded areas where the bats roost in summer — usually alone or in small groups, nestling beneath bark or in tree cavities and crevices. Emerging at dusk, they feed on moths, beetles and other insects.

Under the Endangered Species Act, federal agencies are required to consult with the Fish and Wildlife Service to be sure projects that they fund or authorize — such as timber harvests, prescribed fires and highway construction — will not jeopardize a listed species’ existence.

For nonfederal landowners, actions that could result in unintentional kills could be allowed but will require permits.

Turbines also a threat

The Fish and Wildlife Service said it will also work with wind energy companies to reduce the likelihood that bats will strike turbines. These collisions are currently a threat in roughly half of the northern long-eared bat’s range, an area likely to grow as wind energy development expands.

The service has approved nearly two dozen plans allowing wind energy and forestry projects to proceed after steps were taken to make them more bat-friendly, said Karen Herrington, Midwest regional coordinator for threatened and endangered species.

Operators can limit the danger by curtailing blade rotation during bats’ migration season and when winds are low.

Research continues for methods to fight white-nose syndrome, including development of a vaccine. The service has distributed more than $46 million for the campaign, which involves around 150 agencies, private organizations and Native American tribes.

“We have to find a cure for white-nose syndrome that is killing our bats and we have to protect the forests where they live,” said Ryan Shannon, senior attorney at the nonprofit Center for Biological Diversity. “This endangered listing will help on both counts.”

Source: Voice of America

November 29, 2022

EYES ON IRAN ART ACTIVATION FACES THE U.N. IN NEW YORK

AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) — Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 – January 1, 2023.

Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. ‘Eyes in the Sky’ flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on December 4. Eyes on Iran aims to amplify the mission of Woman, Life, Freedom, a campaign demanding that the Islamic Republic of Iran is removed from the Commission on the Status of Women.

The New York installation was unveiled at an event featuring former U.S. Secretary of State Hillary Rodham Clinton, Human Rights Lawyer and Director of the Strategic Litigation Project at the Atlantic Council Gissou Nia, artists Sheida Soleimani and Shirin Neshat, actor and singer Sepideh Moafi and more at FDR Four Freedoms State Park with a performance by Grammy award-winner Jon Batiste.

“We are calling on the world to take more action, starting at the United Nations. We must remove Iran from the U.N.’s Commission on the Status of Women. The fact that Iran is a member is a bitter irony,” said Clinton. “What we are seeing is a revolution led by young women who are just not willing to live with the loss of freedom being imposed upon them.”

November 28 is significant because it is the anniversary of the 1943 Tehran Conference where Allied leaders, Franklin D. Roosevelt, Winston Churchill and Joseph Stalin met in Tehran to coordinate the Allied military strategy and also stated a shared desire for the maintenance of the independence, sovereignty, and territorial integrity of Iran. Today, Woman, Life, Freedom shares the call for human rights for the people of Iran.

“The world’s eyes have been focused on the courage of Iranian citizens in their quest for freedom, in the face of increasingly grave danger,” said human rights activist Nazanin Afshin-Jam Mackay. “The Islamic Republic has censored them and attempted to blind the world to the potential of this movement. ‘Eyes on Iran’ is our response to their call for a free Iran.”

“When we say that we must keep our ‘Eyes on Iran,’ we mean that what is happening deserves not only our attention but our vision. In solidarity with the courageous Iranians who are risking their lives to express their human rights, many artists throughout the diaspora and beyond are bringing our vision to bear to ensure international audiences and institutions remain aware of what is happening in Iran, in their eyes and in their hearts, and feel moved to respond,” says artist Shirin Neshat.

An interactive installation by artist JR will take place on December 4 at FDR Four Freedoms State Park. Eyes on Iran aims to amplify the mission of Woman, Life, Freedom, a campaign demanding that the Islamic Republic of Iran is removed from the Commission on the Status of Women. Additional artists featured online including Emily Elise, Mahdis Nikou, Priscillia Kounkou Hoveydam, Ernesto Yerena, Hourdad, Golnar Adili, and Anonymous Artists.

In October, the campaign published a two-page ad in The New York Times with a petition signed by women leaders from more than 14 countries, including Clinton, demanding the U.N. Member States remove the Islamic Republic of Iran from the Commission on the Status of Women. Within days, Prime Minister Jacinda Ardern of New Zealand, Canadian Deputy Prime Minister Chrystia Freeland, and Foreign Affairs Minister Melanie Joly, along with nearly 100,000 others, signed the petition.

The Woman, Life, Freedom campaign is a partnership between artist collective For Freedoms, a coalition of Iranian women leaders and Vital Voices Global Partnership, a non-profit elevating women leaders.

Key Links:

Press Images

Woman Life Freedom Website

Press Release: Open Letter Calling for the Immediate Expulsion of the Islamic Republic of Iran from the UN Commission on the Status of Women

About Our Partners:

For Freedoms is an artist collective that centers art and creativity as a catalyst for transformative connection and collective liberation. By wielding the power of art, we aim to deepen and expand our capacity to interrogate what is and imagine what could be. Together, we seek infinite expansion.
www.forfreedoms.com

Vital Voices Global Partnership celebrates 25 years of directly investing in more than 20,000 women leaders across 184 countries since 1997. Driven by the universal truth that women are the key to progress in their communities and nations cannot move forward without women in leadership positions, Vital Voices has provided early support for leaders who went on to become Nobel Peace Prize Laureates, U.S. Youth Poet Laureates, prime ministers, award-winning innovators, pioneering human rights defenders, and breakthrough social entrepreneurs.
www.vitalvoices.org

Four Freedoms Park Conservancy (FFPC), founded in 2011, operates under a Friends Agreement with New York State Parks to produce and curate public programs at Franklin D. Roosevelt Four Freedoms State Park. The park, designed by American modernist architect Louis Kahn, is among the greatest architectural masterpieces in New York City. By leveraging this spectacular architecture and the unique location of the park, the Conservancy produces events, installations,public art, and partners with local organizations that, together, serve a singular purpose: igniting the conversation around the Four Freedoms and the legacy of President Franklin D. Roosevelt.
www.fdrfourfreedomspark.org

The New York State Office of Parks, Recreation and Historic Preservation oversees more than 250 parks, historic sites, recreational trails, golf courses, boat launches and more, which are visited by more than 78 million people annually. For more information on any of these recreation areas, visit www.parks.ny.gov, download the free NY State Parks Explorer mobile app or call 518.474.0456. Also, connect on Facebook, Instagram and Twitter.

Attachments

Sarah Brown McLeod
DEPARTMENT PR
sarah@department-pr.com

GlobeNewswire Distribution ID 8704529